Pacira Biosciences Inc (PCRX) Quarterly and Annual Segment Results by Country and Region - CSIMarket
CSIMarket
 
Pacira Biosciences inc   (NASDAQ: PCRX)

Select the Financial Report: Select the Period:


Description of Pacira Biosciences Inc's Business Segments


Pacira Biosciences Inc. stands out in the pharmaceutical landscape as a pioneering company focused on the development and commercialization of innovative solutions specifically dedicated to pain management and postsurgical care. The companys commitment to addressing the opioid crisis while providing effective pain relief options has positioned it as a significant player in healthcare. Below is an extensive description of the segments, products, and services that Pacira Biosciences Inc. offers.

Segments:

1. EXPAREL Segment:
- Overview: At the heart of Paciras offerings is EXPAREL, a non-opioid, long-acting local anesthetic designed to provide effective pain relief following surgical procedures. It employs a unique delivery system that extends the duration of pain relief, allowing patients to manage postoperative pain without the need for narcotics.
- Application: EXPAREL is primarily utilized in various surgical settings including hospitals, ambulatory surgery centers, and outpatient facilities. Its application spans multiple specialties such as orthopedic surgery, general surgery, and plastic surgery.

2. IV and Regional Anesthetics Segment:
- Overview: This segment encompasses additional pharmaceutical formulations that provide localized anesthesia. Pacira leverages advanced drug delivery systems to create formulations that yield long-lasting analgesia, thereby enhancing patient comfort and postoperative recovery.
- Key Products:
- DEXPATM: This long-acting anesthetic is aimed to relieve pain for extended periods (up to 72 hours), proving advantageous in surgical scenarios that typically involve significant postoperative discomfort. It particularly shines in comprehensive procedures such as spine surgeries and knee replacements.
- DepofoamTM: Incorporating the innovative Depofoam technology, this product allows for a controlled and prolong release of the anesthetic. Depofoam serves as a delivery platform that enhances patient outcomes by improving pain management post-surgery, applicable in challenging surgical contexts.

Products:

1. EXPAREL:
- Mechanism: EXPAREL utilizes liposomal encapsulation to deliver bupivacaine, creating an effective barrier against pain signals for an extended duration. This mechanism decreases the urge for running through a typical opioid pathway in managing pain.
- Benefits: By minimizing reliance on opioids, EXPAREL not only improves patient experiences but also addresses the broader healthcare challenge of opioid-related side effects and dependency.

2. DEXPATM:
- Functionality: With its ability to provide pain relief lasting up to three days, DEXPATM becomes instrumental in surgeries known for aftercare complexities. It is vital in ensuring patient comfort and reducing hospital stays, leading to better outcomes in recovery trajectories.

3. DepofoamTM:
- Advantages: The unique Depofoam technology enables a predictable release profile that can be tailored to various surgical needs. This product is indicative of Pacira’s commitment to not merely treating pain but transitioning to a holistic approach to healthcare.

Services:

1. Pain Management Education:
- Target Audience: This initiative is geared towards healthcare professionals—surgeons, anesthesiologists, and nurses—equipping them with knowledge centered on pain management strategies. The aim is to foster an understanding of the operational use of Pacira’s products and enhancing overall patient care.

2. Clinical Support:
- Patient Resources: Pacira provides comprehensive resources for patients that encompass educational materials, personalized care plans, and direct channels for patient inquiries. By doing so, the company ensures patients are well-informed about their pain management options, enhancing their confidence in the postoperative phase.

3. Healthcare Provider Collaboration:
- Partnerships: The company takes a collaborative approach by working directly with healthcare institutions to integrate products into their pain management protocols, enabling optimized care pathways that highlight the importance of multimodal analgesia.

Overall Impact:
Pacira Biosciences Inc. is not just focused on product development but is integral to shaping the future of pain management strategies. The companys emphasis on innovative, non-opioid solutions allows for substantial progress in how postoperative pain is managed, fostering a safer environment for surgical patients. This progressive approach to medication and support services signifies a transformative shift in pharmaceutical practices, with Pacira at the forefront of delivering solutions aimed at improving recovery, enhancing the quality of life, and minimizing the risks associated with traditional opioid medications.


Composition of Pacira Biosciences inc Revenues by Segments

 
Product    191.2 % of total Revenue
Royalty    0.99 % of total Revenue
EXPAREL    151.3 % of total Revenue
ZILRETTA    30.88 % of total Revenue
iovera°    6.75 % of total Revenue
Bupivacaine liposome injectable suspension    2.27 % of total Revenue
Reportable    192.19 % of total Revenue

Q2 three months ended (Jun 30 2026)
Revenues by Business Segments Revenues
(in millions $)
%
(of total Revenues)
Product 367.87 191.2 %
Royalty 1.91 0.99 %
EXPAREL 291.10 151.3 %
ZILRETTA 59.42 30.88 %
iovera° 12.98 6.75 %
Bupivacaine liposome injectable suspension 4.38 2.27 %
Reportable 369.78 192.19 %
Total 192.40 100 %




Q2 three months ended (Jun 30 2026)
Revenue Growth rates by Segment Y/Y Revenue
%
Q/Q Revenue
%
Product - -
Royalty - -
EXPAREL 103.68 % 103.18 %
ZILRETTA 89.62 % 121.97 %
iovera° - -
Bupivacaine liposome injectable suspension 761.22 % 277.48 %
Reportable - -
Total 6.24 % 8.47 %




Q2 three months ended (Jun 30 2026)
Income by Business Segments Income
(in millions $)
%
(Profit Margin)
Total 4.65 2.42 %




Q2 three months ended (Jun 30 2026)
Income Growth rates by Segment Y/Y Income
%
Q/Q Income
%
Total - 59.57 %




Annual Report on Pacira Biosciences inc Divisions, Sales by Country

 
EXPAREL   EXPAREL Segment contribution to total sales 79.17 % of total Revenue
ZILRETTA   ZILRETTA Segment contribution to total sales 16.06 % of total Revenue
Bupivacaine liposome injectable suspension   Bupivacaine liposome injectable suspension Segment contribution to total sales 0.95 % of total Revenue
iovera   iovera Segment contribution to total sales 3.33 % of total Revenue
Net product sales   Net product sales Segment contribution to total sales 99.51 % of total Revenue


Twelve months ended 2025
PCRX s Annual Revenue by Geography and Business Segments Sales
(in millions $)
%
(of total Sales)
EXPAREL 575.13 79.17 %
ZILRETTA 116.63 16.06 %
Bupivacaine liposome injectable suspension 6.91 0.95 %
Total 726.41 100 %
iovera 24.18 3.33 %
Net product sales 722.85 99.51 %


Twelve months ended 2025
PCRX s Annual Income by Country and Business Segments Income
(in millions $)
%
(Profit Margin)
Total 7.03 0.97 %

Twelve months ended 2025
Annual Revenue and Income Growth by Country and Business Segments % Y/Y Sales Growth % Y/Y Income Growth
EXPAREL 4.77 % -
ZILRETTA -1.23 % -
Bupivacaine liposome injectable suspension -5.59 % -
Total 3.63 % -
iovera 5.98 % -
Reportable Segment - -
Net product sales 3.68 % -



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.